NLS Medtech News

Glycorex Transplantation is broadening its strategy to develop standardized, universal blood products for civilian healthcare, emergency preparedness, and military medicine. The work will be carried out through its new subsidiary, Glycorex Universal Blood Products (UBP).

Norwegian medtech company Medistim reported record third-quarter revenue of NOK 210.0 million, up 25.9% from NOK 166.8 million a year earlier. Operating profit rose 55.7% to NOK 63.1 million, and the board decided on the company’s first quarterly dividend, NOK 2.50 per share.

Swedish medtech company Getinge raised its adjusted EBITA margin to 15.1% in the third quarter of 2026, from 13.1% a year earlier, while organic sales grew 2.1%. The company kept its forecast of 3–5% organic sales growth for the full year.

Spago Nanomedical’s Board of Directors has resolved to apply for delisting from the Nasdaq First North Growth Market, subject to approval at an extraordinary general meeting on November 19, 2026. The goal is to make it easier to finance the next phase of Tumorad’s development with long-term specialist investors.

UK digital pathology provider Diagnexia has signed an agreement to use Swedish medical imaging IT company Sectra’s cloud-based Image Exchange Portal to receive, send and report on pathology cases from NHS organizations.

SciBase has secured its first positive US medical policy from a major Blue Cross Blue Shield organization: Highmark will cover the company's Nevisense skin lesion assessment for patients being evaluated for possible melanoma.